10 evidence based critical care, 3e, 2015

Paul Ellis Marik

Evidence-Based
Critical Care

Third Edition

123


Evidence-Based Critical Care


Paul Ellis Marik

Evidence-Based Critical Care
Third Edition


Paul Ellis Marik
Division of Pulmonary and Critical Care Medicine
Eastern Virginia Medical School
Norfolk, VA, USA

ISBN 978-3-319-11019-6
ISBN 978-3-319-11020-2 (eBook)
DOI 10.1007/978-3-319-11020-2
Springer Cham Heidelberg New York Dordrecht London
Library of Congress Control Number: 2014956872
© Springer International Publishing Switzerland 2015
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of

the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation,
broadcasting, reproduction on microfilms or in any other physical way, and transmission or information
storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology
now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection
with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and
executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this
publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s
location, in its current version, and permission for use must always be obtained from Springer.
Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations
are liable to prosecution under the respective Copyright Law.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication
does not imply, even in the absence of a specific statement, that such names are exempt from the relevant
protective laws and regulations and therefore free for general use.
While the advice and information in this book are believed to be true and accurate at the date of
publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for
any errors or omissions that may be made. The publisher makes no warranty, express or implied, with
respect to the material contained herein.
Printed on acid-free paper
Springer is part of Springer Science+Business Media (www.springer.com)


Learning without thinking is useless. Thinking without learning is dangerous.
—Confucius, Chinese Philosopher (551–479 BC)
To cure sometimes, to relieve often, to comfort always.
—Hippocrates, Greek Physician, Father of Western Medicine (460–370 BC)


This book is dedicated to the memory
of my father, Colin Sigmund Marik,
a man of great intellect and wit.

Preface to Third Edition

After completing the Second Edition of The Handbook of Evidence Based Critical
Care in 2009, I swore that I would rather stick needles in both my eyes than author
another updated version of the book. But here we are in 2015 with the Third Edition
of Evidence-Based Critical Care (no longer a handbook). So what made me change
my mind? Most importantly, you, my dedicated readers, have implored me to update
the book; I was told, “Medicine as we know it would be incomplete without an
updated version.” Your enthusiastic and positive feedback was the driving factors
which led me to consider writing this revision. In addition, in the last 5 years we
have witnessed a remarkable refinement in the management strategies of critically
ill patients best characterized as “Less is More” (see Chap. 2). At the same time we
have realized that while many of our patients survive their ICU stay, many have
significant residual functional and cognitive disabilities. These changes in our
approach and understanding of critical illness have necessitated the updated Third
Edition of Evidence-Based Critical Care.
However, the basic guiding principles of Critical Care Medicine have not
changed; compassionate, dedicated and thoughtful clinicians, who evaluate the
functioning of the “whole” patient, ponder their disease processes and pathophysiology and provide the highest level of Evidence-Based interventions with the goal
of restoring the patient to a quality of life which he/she values.
Due to the vast number of therapeutic interventions that ICU physicians make
daily, the topics are presented as narrative summaries of the best available evidence
rather than as systematic reviews of each and every intervention. In keeping with the
goal of providing an evidence-based approach to critical care, references are
provided to support the evidence presented. In writing this book my goal has been
to take issues that appear complex and make them as simple as possible.

ix

x

Preface to Third Edition

It appears to me that those who really don’t have a good understanding of the
complexities of physiology, pathophysiology and patient care make things so complicated that they themselves don’t understand what they are trying to convey. This
concept is exemplified by the following quotes:
Make everything as simple as possible, but not simpler
If you can’t explain it simply, you don’t understand it well enough
Albert Einstein, Theoretical Physicist, 1879–1955

Evidence-Based Critical Care is not a reference text but presents a practical
evidence-based approach to the management of critically ill ICU patients. The
focus of this book is on issues that pertain specifically to the ICU. As such, the
reader is referred to standard medical and surgical texts as well as online resources
for more complete information on the wide spectrum of conditions and diseases
from which ICU patients may suffer. While all attempts have been made to be
current, due to the exponential growth of medical knowledge some of the information presented may already be outdated when this book comes to print. The reader
should therefore keep up-to-date with the current medical literature.
The guidelines presented in the book are not meant to replace clinical judgment,
but rather to provide a framework for patient management. Individual clinical situations can be highly complex and the judgment and wisdom of an experienced and
knowledgeable intensivist with all available information about a specific patient is
essential for optimal clinical management.
Norfolk, VA, USA

Paul Ellis Marik

Acknowledgements

This book recognizes my mentors and students who have taught me everything
I know and inspired me to learn even more.

xi


A Note to the Reader

The author and publisher have made every attempt to check information and
dosages for accuracy. Because information and the science of pharmacology is
continually advancing, our knowledge base continues to expand. Therefore, we
recommend that the reader check all information and all product information for
changes, especially changes in dosages or administration before administering any
medication.

xiii


Contents

Part I

General ICU Topics

1

Evidence Based Critical Care ................................................................
References .................................................................................................

3
6

2

“Less Is More”: The New Paradigm in Critical Care .........................
References .................................................................................................

7
8

3

“Classic” Papers ......................................................................................

13

4

Critical Care Medicine 101 ....................................................................
Factors to Consider When a Patient is Admitted to the ICU.....................
Initial “Generic” Treatment Orders ...........................................................
Reference ..................................................................................................

19
20
20
21

5

House Officers Guidelines 1: Housekeeping .........................................
Admission History and Physical Examination .........................................
Daily Examination ....................................................................................
General ..................................................................................................
Vital Signs (24 h Min and Max and Current) .......................................
Additional Observations .......................................................................
The Ventilator ........................................................................................
Heart......................................................................................................
Chest .....................................................................................................
Abdomen ...............................................................................................
CNS .......................................................................................................
Importance of the Daily Neurological Examination .............................
Laboratory Tests ........................................................................................
Imaging .....................................................................................................
Presenting on Daily Rounds......................................................................
New Admissions ...................................................................................

23
23
24
24
24
24
25
25
25
25
26

26
26
27
27
27

xv


xvi

Contents

Follow Up Patients ................................................................................
Clinical Pearls ...........................................................................................
References .................................................................................................

28
28
28

6

House Officers Guidelines 2: Procedures .............................................
Murphy’s Laws of Procedures ..................................................................
Central Venous Access ..............................................................................
Subclavian Vein Catheterization ...........................................................
Internal Jugular Vein Catheterization ....................................................
Femoral Vein Catheterization................................................................
Complications of Central Venous Access .............................................

Arterial Catheters ......................................................................................
Naso/Oro Gastric Tubes ............................................................................
Feeding Tubes ...........................................................................................
Thoracentesis and Paracentesis .................................................................
Clinical Pearls .......................................................................................
References .................................................................................................

29
29
30
31
32
33
34
34
35
36
36
37
37

7

Admission-Discharge Criteria ...............................................................
ICU Admission Criteria ............................................................................
Prioritization of Potential ICU Admissions ..............................................
Priority 1 ...............................................................................................
Priority 2 ...............................................................................................
Priority 3 ...............................................................................................
Priority 4 ...............................................................................................

Transfer from Another Hospital: Variable Priority ...............................
Disease Specific Indications for ICU Admission ......................................
Cardiovascular System ..........................................................................
Pulmonary System ................................................................................
Neurological Disorders .........................................................................
Drug Ingestion and Drug Overdose ......................................................
Gastrointestinal Disorders.....................................................................
Endocrine ..............................................................................................
Renal Disorders.....................................................................................
Postoperative Care ................................................................................
Miscellaneous .......................................................................................
Physiologic Indication for ICU Admission ...............................................
Discharge Criteria .....................................................................................
Reference ..................................................................................................

39
39
40
40
40
40
41
41
41
41
42
42
42
43
43

43
44
44
44
44
45

8

Chronic Critical Illness and the Long Term Sequela
of Critical Care ........................................................................................
Neuromuscular Abnormalities ..................................................................
Critical Illness Polyneuropathy .............................................................
Critical Illness Myopathy (See also Chap. 32 on Nutrition) .................
Brain Dysfunction .................................................................................
“Prevention” of CCI ..................................................................................

47
49
49
49
51
51


Contents

9

10

xvii

Management of CCI..................................................................................
Testing ...................................................................................................
General Management ............................................................................
Stress Hyperglycemia ...........................................................................
Metabolic Bone Disease .......................................................................
Anabolic Steroids ..................................................................................
Exercise Program ..................................................................................
References .................................................................................................

52
52
53
53
53
54
54
54

Fluid Responsiveness and Fluid Resuscitation .....................................
Echocardiographic Assessment of Fluid Responsiveness .........................
Static Echocardiographic Parameters....................................................
Dynamic Echocardiographic Parameters ..............................................
Passive Leg Raising (PLR) .......................................................................
The Fluid Challenge..................................................................................
Fluid Boluses in Volume Responsive Patients ..........................................
What Type of Fluid? .................................................................................
Lactated Ringer’s (Hartmann’s Solution) vs. 0.9 % NaCl

(Ab-Normal Saline) ..............................................................................
Complications Associated with 0.9 % NaCl vs. Lactate
Ringers Solution........................................................................................
Renal Failure .........................................................................................
Hyperchloremic Metabolic Acidosis and DEATH ................................
Lactate Generates HCO3− .......................................................................
Ringer’s Lactate and Kidney Disease ...................................................
Ringers Lactate and Liver Disease........................................................
Coagulopathy ........................................................................................
Lactate as a Metabolic Fuel ..................................................................
Albumin ....................................................................................................
Hetastarches (HES) ...................................................................................
So, Which Fluid?.......................................................................................
Resuscitation in Specific Disease States ...................................................
Hemorrhage...........................................................................................
Traumatic Brain Injury..........................................................................
Dehydration...........................................................................................
Sepsis (and SIRS) .................................................................................
Burns .....................................................................................................
Management of Oliguria ...........................................................................
Management of Volume Overload/Acute Pulmonary Edema ...............
References .................................................................................................

57
66
66
66
67
69
71

72

Assessment of Cardiac Function and Cardiac Output ........................
Echocardiographic Assessment of Cardiac Function ................................
Methods of Measuring Cardiac Output.....................................................
Pulmonary Artery Catheter ...................................................................
Transpulmonary Thermodilution ..........................................................

89
89
90
90
91

72
73
73
73
73
74
75
75
75
76
77
78
78
78
79
79

80
80
80
81
81


xviii

Contents

Pulse Contour Analysis .........................................................................
Esophageal Doppler ..............................................................................
USCOM ................................................................................................
Bioreactance ..........................................................................................
Utility of Cardiac Output monitoring .......................................................
Determining Fluid and Inotrope Responsiveness .................................
Driving up CI to Supranormal Values ...................................................
References .................................................................................................

92
93
93
94
94
94
94
95

11

Peri-operative Fluid Optimization ........................................................ 99
References ................................................................................................. 104

12

Sepsis ........................................................................................................
Bacteriology and Sites of Infection...........................................................
Pathophysiology of Sepsis ........................................................................
Septic “Cardiomyopathy” .....................................................................
Complications Associated with Sepsis..................................................
Clinical Features and Diagnosis of Sepsis ................................................
Organ Dysfunction in Severe Sepsis/Septic Shock ...............................
Management of Sepsis ..............................................................................
Antibiotic Therapy ................................................................................
Fluid Therapy (See also Chap. 9)..........................................................
Vasopressors and Inotropic Agents .......................................................
B-Blockers and Phenylephrine in Septic Shock ...................................
Resuscitation End-Points ......................................................................
The Dangers of a HIGH CVP ...............................................................
Does Tissue Hypoxia and Mitochondrial Dysfunction
Exist in Sepsis? .....................................................................................
Case Example............................................................................................
References .................................................................................................

13 The Stress Response, Stress Hyperglycemia
and Stress Hyperlactemia..........................................................................
The Stress Response .................................................................................
Cardiovascular Effects of the Stress Response .....................................
Immune Effects of the Stress Response ................................................

Metabolic Effects of the Stress Response .............................................
Stress Hyperglycemia ...............................................................................
Treatment of “Stress Hyperglycemia” ..................................................
So What to Do! .....................................................................................
How to Achieve These Goals? ..............................................................
Glucose Control and Steroids ...............................................................
Stress Hyperlactemia ................................................................................
Lactate Metabolism...............................................................................
Lactate as a Marker of Illness Severity .................................................
Lactate as a Marker of Metabolic Stress ...............................................

107
108
109
109
111
112
112
115
118
119
124
128
129
130
133
136
137
149
149

152
152
153
153
155
157
157
158
158
159
160
161


Contents

Lactate as a Metabolic Fuel ..................................................................
Heart Metabolism and Lactate ..............................................................
Brain Metabolism and Lactate ..............................................................
References .................................................................................................
14

15

Understanding the Vital Signs: BP, HR, RR, TEMP,
SaO2 … and SV .......................................................................................
Blood Pressure ..........................................................................................
The Brain-Heart Distance and the Giraffe Theory of Blood Pressure
Determination in Humans .....................................................................
What’s a Normal Blood Pressure? ........................................................

BP Thresholds for the Intensivist/Anesthesiologist ..............................
Non-Invasive Blood Pressure (NIBP) vs Arterial Line Blood Pressure
(IAP) and Systolic Blood Pressure (SBP) vs Mean Arterial
Pressure (MAP).....................................................................................
Central vs Peripheral Blood Pressure Measurement .............................
Blood Pressure Autoregulation .............................................................
MAP, Organ Failure and Death .............................................................
Circulatory Shock .....................................................................................
Pulse Rate..................................................................................................
Respiratory Rate (& Pattern) ....................................................................
Temperature ..............................................................................................
Pulse Oximetry..........................................................................................
Too Much Oxygen Kills............................................................................
Analysis of the Oximetric Waveform....................................................
Stroke Volume: The 6th Vital Sign ............................................................
Putting the Vital Signs Together................................................................
Early Warning Scoring Systems and Rapid Response Teams...............
References .................................................................................................
Management of Pain, Agitation and Delirium .....................................
Assessing the Level of Pain and Sedation.................................................
The Ramsey Sedation Scale ..................................................................
The Richmond Agitation-Sedation Scale (RASS) ................................
Sedation Vacations ....................................................................................
Non-pharmacologic Interventions.............................................................
Delirium ....................................................................................................
Sedative and Analgesics Agents ................................................................
Lorazepam.............................................................................................
Midazolam ............................................................................................
Propofol.................................................................................................
Dexmedetomidine .................................................................................

Haloperidol ...........................................................................................
Fentanyl.................................................................................................
Morphine ...............................................................................................
Meperidine ............................................................................................

xix

162
163
163
164
169
169
170
171
172

172
173
174
175
176
177
178
179
179
184
188
189
190

191
192
197
200
201
201
202
202
202
205
205
206
206
207
208
208
208
208


xx

Contents

Neuromuscular Blockade .......................................................................... 209
Neuromuscular Blocking Agents .......................................................... 209
References ................................................................................................. 210
16

Hospital Acquired Infections and Their Prevention ............................

Colonization with Multidrug Resistant Organisms...................................
Handwashing and Infection Control Measures .........................................
Handwashing.........................................................................................
Chlorhexidine Bathing ..........................................................................
Gloves and Gowns and Healthcare Provider Apparel ...........................
Universal Screening for MDR’s and “Protective Isolation” .................
Oropharyngeal and Gastrointestinal Decolonization ............................
Private Rooms and Environmental Control ..........................................
Central Line Associated Blood Stream Infection......................................
Management of CLABSI’s ...................................................................
Antibiotics Lock Therapy .....................................................................
Prevention of CLABSI ..........................................................................
Catheter Associated Urinary Tract Infection.............................................
Ventilator Associated Pneumonia .............................................................
Pathogenesis of VAP .............................................................................
Diagnosis of VAP ..................................................................................
Treatment ..............................................................................................
General Concepts for the Antimicrobial Treatment of VAP .................
Empiric Antibiotic Choices ...................................................................
“Specific” Interventions for Prevention of VAP....................................
Clostridium difficile Infection ...............................................................
Laboratory Diagnosis ............................................................................
Sigmoidoscopy ......................................................................................
Treatment ..............................................................................................
Fidaxomicin ..........................................................................................
Adjunctive Treatment Options ..............................................................
Probiotics ..............................................................................................
Surgical Intervention .............................................................................
Nosocomial Rhinosinusitus ......................................................................
References .................................................................................................

Part II
17

213
215
216
216
216
217
217
218
219
220
224
225
225
227
229
230
232
234
234
235
235
239
241
242
243
244

244
245
245
246
248

Pulmonary

The Bacterial Pneumonias: A New Treatment Paradigm ...................
Unified Treatment Algorithm ....................................................................
No Risk Factors for a CAP-DRP ..........................................................
Risk Factors for CAP-DRPs .................................................................
Influenza (Co-Existent or Influenza Pneumonia) ..................................
Diagnostic Testing of Hospitalized Patients with Pneumonia ..............
Non-Infectious Diseases Masquerading as Pneumonia ........................
Special Considerations ..............................................................................
Severe CAP with no MDR Risk Factors ...............................................

261
263
263
264
264
265
265
266
266


Contents

xxi

Community-Acquired MRSA Pneumonia (CA-MRSA) ......................
Aspiration Pneumonia...........................................................................
Nursing Home-Acquired Pneumonia ....................................................
Persistent Temperature/Failure to Respond to Rx.................................
Unusual Pathogens ................................................................................
Complicated Pleural Effusion/Empyema ..............................................
References .................................................................................................

266
267
269
269
270
271
271

18

Fever .........................................................................................................
Common Misconception and Fables .........................................................
Pathogenesis of Fever ...............................................................................
Treatment of Fever ................................................................................
Causes of Fever in the ICU .......................................................................
Infectious Causes of Fever in the ICU ..................................................
Non-Infections Causes of Fever in the ICU ..........................................
Non-Infectious Causes of Fever ............................................................
An Approach to the Febrile ICU Patient ...................................................

Clinical Pearls ...........................................................................................
References .................................................................................................

275
275
276
276
278
279
279
279
286
288
288

19

Mechanical Ventilation 101 ....................................................................
Alveolar Overdistension Damages Normal Lungs ...................................
Ventilator Variables and Modes of Ventilation ..........................................
Ventilator Variables (See Table 19.1) ....................................................
Common Modes of Mechanical Ventilation .............................................
Positive End-Expiratory Pressure (PEEP) ............................................
Auto-PEEP ................................................................................................
Monitoring Patients Undergoing Mechanical Ventilation.....................
Sudden Increase in Airway Pressure and/or Fall
in Arterial Saturation .............................................................................
When to Perform a Tracheostomy ............................................................
Timing of Tracheostomy in the Critically Ill ........................................
References .................................................................................................

291
293
293
297
299
303
305
306

Non-invasive Ventilation .........................................................................
Set Up........................................................................................................
Initial Settings ...........................................................................................
Indications of NIV ....................................................................................
COPD Exacerbations ............................................................................
Acute Cardiogenic Pulmonary Edema ..................................................
Facilitating Extubation in COPD Patients ............................................
Immunocompromised Patients..............................................................
Post-operative Patients ..........................................................................
When to Use NIV......................................................................................
Hypercapnic Respiratory Failure ..........................................................
Hypoxemic Respiratory Failure ............................................................

311
312
312
313
313
313
313

314
314
315
315
315

20

307
307
308
308


xxii

Contents

Contraindications to NIPPV ................................................................. 315
Success and Failure Criteria for NIPPV ............................................... 316
References ................................................................................................. 316
21

Liberation (Weaning from Mechanical Ventilation) ............................
General Concepts ......................................................................................
Effect of Liberation on Oxygen Consumption and Cardiac Function ..
Fluid Overload and Liberation Failure..................................................
Vasopressors and Inotropic Agents and Weaning .................................
Mechanical Ventilation Liberation Process ..............................................
“Readiness” Testing ..............................................................................

Spontaneous Breathing Trials ...............................................................
Causes of Liberation Failure .................................................................
Early Extubation Followed by NIV in COPD ......................................
NIV for Persistent Liberation Failure ...................................................
Extubation Failure .................................................................................
Patients at High Risk of Extubation Failure..........................................
The Cuff Leak Test....................................................................................
Corticosteroids for the Prevention of Post-extubation Stridor ..............
References .................................................................................................

319
319
320
320
321
322
322
323
324
324
324
325
325
326
326
326

22

Arterial Blood Gas Analysis...................................................................

Indications for ABG Sampling..................................................................
ABG Sampling ..........................................................................................
ABG Analysis ...........................................................................................
Alveolar Ventilation ..............................................................................
Oxygenation ..........................................................................................
Acid-Base Balance ................................................................................
A Step Wise Approach to Acid-Base Disorders ........................................
Common Acid Base Disturbances in the ICU...........................................
Metabolic Acidosis................................................................................
Metabolic Alkalosis ..............................................................................
Venous Blood Gas Analysis (VBGs) ........................................................
Mixed Venous/Central Venous Oxygen Saturation ...................................
References .................................................................................................

329
329
330
331
332
332
334
335
338
338
341
342
343
344

23

ARDS........................................................................................................
Definition, Causes and Assessment of Severity ........................................
Definition of ALI According the American European Consensus ........
Acute Lung Injury (ALI) ......................................................................
Acute Respiratory Distress Syndrome (ARDS) ....................................
Pathophysiological Definition of ARDS ...............................................
Causes of ALI .......................................................................................
Management of the Acute Phase of ARDS ...............................................
Ventilatory Strategy ..............................................................................
Pressure Controlled Ventilation.............................................................

349
349
349
349
350
350
351
351
352
355


Contents

xxiii

Airway Pressure Release Ventilation ....................................................
Permissive Hypercapnia ........................................................................

Best PEEP .............................................................................................
Recruitment Maneuvers ........................................................................
Non-Ventilatory Adjuncts to Gas Exchange .............................................
Prone Positioning ..................................................................................
Neuromuscular Blocking Agents ..........................................................
ECMO .......................................................................................................
Corticosteroids ......................................................................................
Inhaled Nitric Oxide .............................................................................
Nebulized Prostacyclin .........................................................................
β2-Adrenergic Receptor Agonists ..........................................................
Surfactant ..............................................................................................
Omega-3 Enteral Nutrition....................................................................
“Our” Approach to Refractory Hypoxemia ..............................................
References .................................................................................................

357
359
359
361
361
361
362
362
363
365
365
365
365
366
366

367

24

COPD Exacerbation ...............................................................................
Common Precipitating Events ..................................................................
Indications for Hospitalization..................................................................
Indications for ICU Admission .................................................................
Treatment ..................................................................................................
Indications for NPPV ................................................................................
Indications for Endotracheal Intubation....................................................
Mechanical Ventilation in COPD ..............................................................
Suggested Initial Settings..........................................................................
References .................................................................................................

373
374
375
375
375
377
377
377
378
378

25

Acute Severe Asthma ..............................................................................
Indications for Admission to the ICU .......................................................

Initial Treatment ........................................................................................
Other Therapeutic Options ....................................................................
Complications of Acute Asthma ...............................................................
Noninvasive Positive-Pressure Ventilation in Status Asthmaticus ............
Indications for Intubation..........................................................................
Sedation Post-intubation ...........................................................................
Mechanical Ventilation..............................................................................
Initial Ventilator Settings...........................................................................
References .................................................................................................

381
382
382
383
384
384
385
386
386
387
388

26

Pleural Effusions and Atelectasis ..........................................................
Pleural Effusions .......................................................................................
Pathophysiology ....................................................................................
Drainage of Pleural Effusion.................................................................
Hepatic Hydrothorax .................................................................................

391
391
391
392
393


xxiv

27

Contents

Alelectasis .................................................................................................
Respiratory Therapy ..............................................................................
Mucolytics.............................................................................................
Bronchoscopy .......................................................................................
Bilevel/APRV ........................................................................................
References .................................................................................................

393
394
394
395
395
396

Venous Thromboembolic Disease: DVT and PE ..................................
Pregnancy, Venous Thromboembolism and Thrombophilias....................
Site of Venous Thrombosis .......................................................................

The Veins of the Lower Limb ...............................................................
Suggested DVT Prophylaxis Protocols .....................................................
Diagnosis of DVT .....................................................................................
Distal Lower Extremity DVT....................................................................
Upper Extremity DVT ..............................................................................
Superficial Phlebitis ..............................................................................
Pulmonary Embolism................................................................................
Diagnosis of Pulmonary Embolism ......................................................
Treatment of Thromboembolic Disease ................................................
Thrombolytic Therapy ..........................................................................
Catheter Directed Clot Fragmentation and Aspiration..........................
Inhaled Nitric Oxide .............................................................................
Vena Caval Interruption ........................................................................
“Absolute Contraindications” for Anticoagulation with Heparin .........
References .................................................................................................

399
399
400
401
405
405
406
406
407
408
408
411
413
418

418
419
419
419

Part III
28

Cardiac

Hypertensive Crises ................................................................................
Definitions .................................................................................................
Pathophysiology ........................................................................................
Clinical Presentation .................................................................................
Initial Evaluation ...................................................................................
Initial Management of Blood Pressure .....................................................
Resident (or Hospitalist) Called to the Floor for High
Blood Pressure: What to Do? ................................................................
Drugs to AVOID ....................................................................................
Recommended Antihypertensive Agents ..............................................
Acute Postoperative Hypertension ........................................................
Pre-operative Hypertension...................................................................
Posterior Reversible Encephalopathy Syndrome (PRES) .........................
Pregnancy-Induced PRES .....................................................................
Drugs Associated with PRES ................................................................
References .................................................................................................

429
429
430

431
432
433
434
436
437
439
440
441
441
442
442


Contents

29

30

xxv

Acute Decompensated Cardiac Failure.................................................
Confirm the Diagnosis of Cardiac Failure ................................................
Evaluation of the Patient with Cardiac Failure .........................................
B-Type Natriuretic Peptides ..................................................................
Echocardiography .................................................................................
Laboratory Testing ................................................................................
Hemodynamic Monitoring ....................................................................
Precipitating Factors .............................................................................

Treatment ..................................................................................................
Acute Phase of Treatment .....................................................................
Treatment of ADHF: Summary.............................................................
Long-Term Management ..........................................................................
Systolic Heart Failure ...........................................................................
Management of Patients with Heart Failure with Preserved Ejection
Fraction (HFpEF) ..................................................................................
Takotsubo Cardiomyopathy ......................................................................
Stressors Reported to Trigger Takotsubo
Cardiomyopathy ....................................................................................
Mayo Clinic Criteria for Takotsubo Cardiomyopathy ..........................
References .................................................................................................

445
446
447
447
448
448
448
449
449
449
456
456
457

Acute Coronary Syndromes ...................................................................
Unstable Angina/NSTEMI ........................................................................
Canadian Cardiovascular Classification of Angina ...................................

Types of Presentations of Unstable Angina ..............................................
Differential Diagnosis ...............................................................................
Electrocardiography ..................................................................................
Tropinins ...................................................................................................
Management of UA/NSTEMI ...................................................................
Risk Stratification..................................................................................
Thrombolysis in Myocardial Infarction
(TIMI) Risk Score .................................................................................
Global Registry of Acute Coronary Events (GRACE)
Risk Model ....................................................................................................
Treatment Approach for UA and NSTEMI
(PER AHA Guidelines) .................................................................................
Class I Recommendations .....................................................................
Class II Recommendations ...................................................................
Treatment Approach to STEMI (PER AHA Guidelines) ..........................
Class I Recommendations .....................................................................
Class II Recommendations ...................................................................
Complications Following STEMI .............................................................
Recurrent Chest Pain Post-AMI............................................................
Mitral Regurgitation ..............................................................................

471
471
472
472
472
472
473
473
473

461
462
462
464
465

473
474
474
474
475
475
475
476
477
477
477


xxvi

31

Contents

Left Ventricular Failure and Low Output States ...................................
Right Ventricular Infarction ..................................................................
Atrial Fibrillation ..................................................................................
References .................................................................................................

478
478
478
479

Arrhythmias ............................................................................................
Arrhythmias and Electrolyte Disturbances ...............................................
Acute Atrial Fibrillation/Flutter ................................................................
Urgent Cardioversion ............................................................................
Rate Control ..........................................................................................
Pharmacologic Cardioversion ...............................................................
Anticoagulation .....................................................................................
Multifocal Atrial Tachycardia (MAT) .......................................................
Paroxysmal Supraventricular Tachycardia (PSVT) ..................................
Management..........................................................................................
SVT Mediated by Accessory Pathways ................................................
Sinus Bradycardia .....................................................................................
Sick-Sinus Syndrome ................................................................................
Accelerated Idioventricular Rhythm .........................................................
Ventricular Premature Complexes and Bigeminy .....................................
Nonsustained Ventricular Tachycardia ......................................................
Sustained Ventricular Tachycardia ............................................................
Polymorphic Ventricular Tachycardia (Torsades De Pointes) ...................
Management..........................................................................................
References .................................................................................................

481
481
482

483
483
484
484
485
485
486
486
487
487
487
487
488
488
489
489
490

Part IV

Gastrointestinal

32

Nutrition in the ICU: It’s Whey Cool....................................................
Myths of Nutritional Support ....................................................................
Important Points to Digest ........................................................................
How Many Calories and How Much Protein to Give? .............................
Muscle Wasting in Critical Illness ........................................................
Factors That Activate Muscle Synthesis by the mTOR Pathway ..........

Bolus vs. Continuous Feeding ..............................................................
So! What is the Best Way to Feed Critically Ill Patients? .........................
The Obese Patient .....................................................................................
The Refeeding Syndrome .........................................................................
References .................................................................................................

493
494
495
498
499
502
504
506
507
507
508

33

Stress Ulcer Prophylaxis .........................................................................
Does SUP Reduce GI Bleeding?...............................................................
Enteral Nutrition and Stress-ulcer Prophylaxis.........................................
Complications Associated with Acid Suppressive Therapy ......................
So! What to Do? ........................................................................................
Complications Associated with Specific Drugs ........................................

513
514
515

516
517
517


Contents

xxvii

H2 Receptor Antagonists (H2RA) ........................................................
Proton Pump Inhibitors (PPIs) ..............................................................
Sucralfate ..............................................................................................
References .................................................................................................

517
518
518
519

34

Acute and Chronic Liver Disease ..........................................................
Chronic Liver Failure ................................................................................
Causes of Cirrhosis ...............................................................................
Metabolic/Hematologic Derangements in Cirrhosis .............................
Spontaneous Bacterial Peritonitis .............................................................
Hepatic Encephalopathy ...........................................................................
Grades of Hepatic Encephalopathy .......................................................
Hepatorenal Syndrome..............................................................................
Hepatorenal Syndrome: Diagnostic Criteria .........................................

Diagnostic Approach.............................................................................
Treatment of HRS .................................................................................
Hepato-adrenal Syndrome ........................................................................
Pulmonary Consequences of Portal Hypertension ....................................
Infection and Cirrhosis..............................................................................
Supportive Care of the Hospitalized Cirrhotic ......................................
The Coagulopathy of Chronic Liver Disease ............................................
Portal Vein Thrombosis .............................................................................
Acute-on-chronic Liver Failure.................................................................
Alcoholic Hepatitis ...................................................................................
Differential Diagnosis ...........................................................................
Management..........................................................................................
Fulminant Hepatic Failure ........................................................................
Causes of Fulminant Hepatic Failure ....................................................
Workup of Patients Presenting with FHF .............................................
Cerebral Edema in FHF ........................................................................
Management of Increased ICP ..............................................................
Supportive Measures .............................................................................
Indications for Liver Transplantation ....................................................
Kings Criteria ........................................................................................
References .................................................................................................

523
523
524
525
525
527
528
529

530
530
531
532
532
532
533
534
535
537
538
539
539
540
541
541
542
543
545
545
546
546

35

GI Bleeding ..............................................................................................
Initial Assessment .....................................................................................
Initial Resuscitation ..................................................................................
Triage of Patients. Who to Admit to the ICU? ..........................................
Upper GI Bleeding ....................................................................................

The Major Causes of UGIB Include .....................................................
Further Management of Upper GI Bleeding (See Fig. 35.1) ....................
Further Management of Bleeding Peptic Ulcers .......................................
Recurrent Hemorrhage ..........................................................................

551
551
553
555
555
556
556
557
559


xxviii

Contents

Further Management of Esophageal Varices............................................. 559
Management of Patients with Lower GI Bleeding.................................... 560
References ................................................................................................. 562
36

Pancreatitis ..............................................................................................
Diagnosis...................................................................................................
Risk Stratification......................................................................................
Complications ...........................................................................................
Management..............................................................................................

References .................................................................................................

565
566
567
568
569
571

37

Diarrhea & Constipation........................................................................
Diarrhea.....................................................................................................
Infectious Diarrhea....................................................................................
“Non-Infectious” Diarrhea ........................................................................
Antibiotic Associated Diarrhea (AAD) .................................................
Enteral Feeding-Associated Diarrhoea .................................................
Management of “Non-Infectious” Diarrhoea........................................
The Use of Probiotics and Prebiotics ........................................................
Constipation ..............................................................................................
References .................................................................................................

575
575
575
576
576
576
576
577

579
580

Part V
38

Miscellaneous

Transfusion of Blood and Blood Products ............................................
Red Blood Cell Transfusions ....................................................................
Why Transfuse? ....................................................................................
Risks Associated with Blood Transfusion (See Fig. 38.1) ........................
Risks Associated with Blood Transfusion.............................................
Transfusion-Associated Immunomodulation ........................................
“Age” of Transfused Red Blood Cells ..................................................
Tolerance to Anemia .............................................................................
Weighing the Risks and Benefits of Blood Transfusion .......................
So, When Should Patients’ Be Transfused? ..........................................
Coagulation Disorders in the ICU.............................................................
Fresh Frozen Plasma .................................................................................
FFP Prior to Invasive Bedside Procedures or Surgery ..........................
Paracentesis ...........................................................................................
Management of Non-therapeutic INRs With or Without Bleeding
(Due to Coumadin Therapy) .................................................................
Platelet Transfusion...................................................................................
Heparin Associated Thrombocytopenia ....................................................
Thrombotic Thrombocytopenic Purpura (TTP) ........................................
Cryprecipitate............................................................................................
References .................................................................................................

585
585
586
586
587
588
590
596
596
597
598
600
601
604
604
606
610
612
614
614


Contents

xxix

39

Adrenal Insufficiency ..............................................................................
Causes of Adrenal Insufficient/Circi .........................................................

Clinical Features of Adrenal Insufficiency/Circi ......................................
Diagnosis of Adrenal Insufficiency/Circi..................................................
Factors Affecting the Response to Corticosteroid Treatment ...................
The Immune Status of the Host ............................................................
Timing of Corticosteroids .....................................................................
Dose and Dosing Strategy .....................................................................
Acute Rebound After Discontinuation of Corticosteroids ....................
Genetic Polymorphisms ........................................................................
Abnormalities of the Glucocorticoid Receptor .....................................
Treatment of Adrenal Insufficiency/CIRCI...............................................
Who to Treat with Steroids? .................................................................
Adverse Effects of Corticosteroids .......................................................
References .................................................................................................

621
622
623
624
625
625
626
626
627
627
628
628
628
630
631

40

Electrolyte Disturbances.........................................................................
Sodium and Water .....................................................................................
Rules of the Game.................................................................................
Hyponatremia............................................................................................
Hypernatremia...........................................................................................
Hypokalemia .............................................................................................
Hyperkalemia ............................................................................................
Hypophosphatemia ...................................................................................
Management..........................................................................................
Hypomagnesemia......................................................................................
Management of Hypomagnesemia .......................................................
Disorders of Calcium Homeostasis...........................................................
Hypocalcemia ...........................................................................................
Should Hypocalcemia Be Corrected in Critically Ill Patients? .............
Treatment ..............................................................................................
Hypercalcemia ..........................................................................................
Treatment ..............................................................................................
Second Line ..........................................................................................
Additional Therapies .............................................................................
References .................................................................................................

635
635
635
635
640
641
641

642
643
643
644
645
646
647
647
648
649
649
650
650

41

Acute Kidney Injury ...............................................................................
Pre-Renal Azotemia ..................................................................................
Contrast Agents and the Kidney ...............................................................
Prevention of Contrast Induced AKI .........................................................
“Common” Nephrotoxic Agents ...............................................................
Management of Established Acute Renal Failure .....................................
When to Initiate Renal Replacement Therapy (RRT) ...............................

653
654
655
655
656
657

657